Nephros Announces Results for Quarter Ended September 30, 2021

Rhea-AI Summary

Nephros, Inc. (NASDAQ: NEPH) reported Q3 2021 financial results with net revenue of $2.6 million, a 24% increase year-over-year. Despite revenue growth, net loss rose to $1.2 million, up 15%. Adjusted EBITDA improved by 22% to ($0.7 million). The company highlighted that year-to-date revenue reached a record high, driven by growth in the water filtration segment, despite challenges from the COVID-19 Delta variant. The FDA is reviewing Nephros’s second-generation HDF system, with expectations for growth in their pathogen detection segment in 2022.

Positive

• Net revenue increased by 24% year-over-year to $2.6 million.
• Year-to-date revenue is the highest in company history, up 23% compared to last year.
• Adjusted EBITDA improved 22% year-over-year.

Negative

• Net loss increased by 15% to $1.2 million.
• Cost of goods sold rose by 37% to $1.2 million.
• Gross margins decreased to 54%, down from 58% in the same period last year.

Third Quarter Net Revenue of $2.6 Million
Up 24% Year-Over-Year and 16% Quarter-over-Quarter 

SOUTH ORANGE, NJ, Nov. 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc.(Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced results for the three months ended September 30, 2021.

Financial Highlights

Water Filtration Business Segment Highlights*

• Net revenue of $2.6 million, an increase of 22%
• Net loss of $0.8 million, an increase of 92%
• Adjusted EBITDA of ($0.3 million) an improvement of 6%

Consolidated Highlights*

• Net revenue of $2.6 million, an increase of 24%
• Net loss of $1.2 million, an increase of 15%
• Adjusted EBITDA of ($0.7 million), an improvement of 22%

*Stated performance is relative to same period prior year (third quarter of 2020)

“Year-to-date revenue through September 30 was the highest in the company’s history, and a 23% over the same period last year,” said Andy Astor, Chief Executive Officer of Nephros. “We are pleased with these results, especially given the prevalence of the COVID-19 Delta variant during the quarter, which may have suppressed our sales. We are optimistic that revenue growth rates will continue to increase, as the pandemic subsides and our markets fully reopen.”

Mr. Astor continued, “Our Pathogen Detection Systems (PDS) business segment generated small but promising new revenue. We believe this relatively young business will see significant growth in 2022. Regarding our second-generation HDF system, the FDA completed its Acceptance Review for the product, and has now entered its Substantive Review phase, which we anticipate will be completed around the end of this year.”

Consolidated Financial Performance for the Quarter Ended September 30, 2021

Net revenue for the quarter ended September 30, 2021 was $2.6 million, compared with $2.1 million in the corresponding period in 2020, an increase of 24%.

Net loss for the quarter ended September 30, 2021 was $1.2 million, compared with a net loss of $1.0 million for the quarter ended September 30, 2020, an increase of 15%. 

Adjusted EBITDA for the quarter ended September 30, 2021 was ($0.7 million), compared with ($1.0 million) during the same period in 2020.

Cost of goods sold for the quarter ended September 30, 2021 was $1.2 million, compared with $0.9 million for the quarter ended September 30, 2020, an increase of 37%. Gross margins for the quarter ended September 30, 2021 were 54%, compared with 58% in the same period in 2020.

Research and development expenses for the quarter ended September 30, 2021 were $0.6 million, compared with $0.8 million during the quarter ended September 30, 2020.

Depreciation and amortization expenses for the quarter ended September 30, 2021 were approximately $50,000, compared with approximately $49,000 for the corresponding period 2020, an increase of 2%.

Selling, general and administrative expenses for the quarter ended September 30, 2021 were $1.9 million, compared with $1.5 million during the same period in 2020, an increase of 23%.

As of September 30, 2021, Nephros had cash and cash equivalents of $7.4 million.

Adjusted EBITDA Definition and Reconciliation to GAAP Financial Measures

Adjusted EBITDA is calculated by taking net (loss) income calculated in accordance with generally accepted accounting principles (“GAAP”) and excluding all interest-related expenses and income, tax-related expenses and income, non-recurring expenses and income, and non-cash items, including depreciation and amortization and non-cash compensation. The following table presents a reconciliation of Adjusted EBITDA to net (loss) income, the most directly comparable GAAP financial measure, for the third quarter of the 2021 and 2020 fiscal years for both Nephros (on a consolidated basis) and the Water Filtration Business Segment:

	3 Months Ended Sep 30,
Water Filtration Business Segment	2021	2020
Net loss	(755)	(394)
Adjustments:
Depreciation of property and equipment	7	7
Amortization of other assets	46	46
Interest expense	10	22
Interest income	(2)	(3)
Change in fair value of contingent consideration	-	(187)
Stock based compensation	257	160
Other noncash items	90	2
Adjusted EBITDA	(347)	(347)

	3 Months Ended Sep 30,
Consolidated Results	2021	2020
Net loss	(1,162)	(1,012)
Adjustments:
Depreciation of property and equipment	7	7
Amortization of other assets	46	46
Interest expense	10	22
Interest income	(2)	(3)
Change in fair value of contingent consideration	-	(187)
Noncash compensation	267	172
Other noncash items	90	2
Adjusted EBITDA	(744)	(953)

Nephros believes that Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to Nephros’s financial condition and results of operations. Management does not consider Adjusted EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recognized in Nephros’s consolidated financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgments by management about which expenses and income are excluded or included in determining Adjusted EBITDA. In order to compensate for these limitations, management presents Adjusted EBITDA in connection with net (loss) income, the most directly comparable GAAP financial measure. Nephros urges investors to review the reconciliation of Adjusted EBITDA to net (loss) income and not to rely on any single financial measure to evaluate the business.

Conference Call Today at 4:30 p.m. ET

Nephros will host a conference call today at 4:30 PM Eastern Time, during which management will discuss Nephros’s financial results and provide a general business overview.

Participants may dial into the call as follows:
Domestic access: 1-844-808-7106
International access: 1-412-317-5285

Upon joining, please ask to be joined into the Nephros conference call.

A replay of the call can be accessed until November 11, 2021 at 1-877-344-7529 or 1-412-317-0088 for international callers and entering replay access code: 10160005. 

An audio archive of the call will be available shortly after the call on the Nephros investor relations page at https://investors.nephros.com/events/.

About Nephros

Nephros, Inc. is a company committed to improving the human relationship with water through leading, accessible technology. We provide innovative filtration and pathogen detection as part of an integrated approach to water safety that combines science, solutions, and support services. Nephros products serve the needs of customers within the healthcare and commercial markets, offering both proactive and emergency responses for water management. 

For more information about Nephros, please visit www.nephros.com.

Forward-Looking Statements

This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’s expected benefits from its recent acquisition of GenArraytion, expected future growth in demand and the timing of such growth, expected future revenue and gross margins, the timing of receiving 510(k) clearance for Nephros’s second-generation HDF Assist Module and the expected timing of commercially launching such product, if cleared, and other statements that are not historical facts, including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including the impact of the ongoing COVID-19 pandemic, uncertainty in clinical outcomes, potential delays in the regulatory approval process, changes in business, economic and competitive conditions, the availability of capital when needed, dependence on third-party manufacturers and researchers, regulatory reforms, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Nephros’s reports filed with the U.S. Securities and Exchange Commission. Nephros does not undertake any responsibility to update the forward-looking statements in this release.

Investor Relations Contacts:

Kirin Smith, President
PCG Advisory, Inc.
(646) 823-8656
ksmith@pcgadvisory.com

Andy Astor, CEO
Nephros, Inc.
(201) 345-0824
andy@nephros.com

NEPHROS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
ASSETS		September 30, 2021		December 31, 2020
Current assets:
Cash and cash equivalents		$7,350		$8,249
Accounts receivable, net		1,555		1,364
Inventory		4,649		5,304
Prepaid expenses and other current assets		67		237
Total current assets		13,621		15,154
Property and equipment, net		382		295
Lease right-use-of assets		814		1,037
Intangible assets, net		1,573		506
Goodwill		759		759
License and supply agreement, net		569		670
Other assets		102		89
Total assets		$17,820		$18,510
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of secured note payable		$243		$229
Accounts payable		641		423
Accrued expenses		573		341
Current portion of lease liabilities		366		332
Total current liabilities		1,823		1,325
Secured note payable, net of current portion		164		364
PPP loan		-		482
Equipment financing, net of current portion		5		7
Lease liabilities, net of current portion		498		759
Total liabilities		2,490		2,937
Commitments and Contingencies
Stockholders' equity:
Preferred stock, $.001 par value; 5,000,000 shares authorized at September 30, 2021 and December 31, 2020; no shares issued and outstanding and September 30, 2021 and December 31, 2020		-		-
Common stock, $.001 par value; 40,000,000 authorized at September 30, 2021 and December 31, 2020; 10,233,083 and 9,873,006 shares issued and  outstanding and September 30, 2021 and December 31, 2020, respectively		10		10
Additional paid-in capital		146,883		144,296
Accumulated other comprehensive income		66		74
Accumulated deficit		(134,683)		(131,858)
Subtotal		12,276		12,522
Noncontrolling interest		3,054		3,051
Total stockholders' equity		15,330		15,573
Total liabilities and equity		$17,820		$18,510

NEPHROS, INC. AND SUBSIDIARIES
CONSOLIDATED OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share amounts)
		Three Months Ended September 30,
		2021		2020
Net revenues:
Product revenues		$2,595		$2,094
Royalty and other revenues		42		27
Total net revenues		2,637		2,121
Cost of goods sold		1,225		896
Gross margin		1,412		1,225
Gross margin %		54%		58%
Operating expenses:
Research and development		632		751
Depreciation and amortization		50		49
Selling, general and administrative		1,892		1,544
Change in fair value of contingent consideration		-		(187)
Total operating expenses		2,574		2,157
Loss from operations		(1,162)		(932)
Interest expense		(10)		(22)
Interest income		2		3
Other income (expense), net		8		(61)
Net loss		(1,162)		(1,012)
Less: Undeclared deemed dividend attributable to noncontrolling interest		(60)		(60)
Net loss attributable to Nephros, Inc. shareholders		(1,222)		(1,072)
Net loss per common share, basic and diluted		$(0.12)		$(0.12)
Weighted average common shares outstanding, basic and diluted		10,044,745		9,039,673
Comprehensive loss:
Net Loss		(1,162)		(1,012)
Other comprehensive (loss) income, foreign currency translation adjustments		(4)		4
Comprehensive loss		(1,166)		(1,008)
Comprehensive loss attirbutable to noncontrolling interest		(60)		(60)
Total comprehensive loss attributable to Nephros, Inc. shareholders		$(1,226)		$(1,068)

FAQ

What was Nephros's net revenue for Q3 2021?

Nephros reported a net revenue of $2.6 million for Q3 2021.

How did Nephros's net loss change in Q3 2021?

Nephros's net loss increased to $1.2 million in Q3 2021, up 15% from the previous year.

What is the adjusted EBITDA for Nephros in Q3 2021?

The adjusted EBITDA for Nephros in Q3 2021 was ($0.7 million), an improvement of 22% year-over-year.

What challenges did Nephros face in Q3 2021?

Nephros faced sales pressure due to the COVID-19 Delta variant during Q3 2021.

What are Nephros's expectations for their pathogen detection segment?

Nephros expects significant growth in their pathogen detection segment in 2022.